An interventional study of Price discounts for SARCs and Price discounts for LARCs in Contraception, Contraception Behavior and Contraceptive Usage, sponsored by World Bank. Completed at 1 site in Cameroon. Open to female participants aged 10 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-05-14.
Sponsored by World Bank · Not applicable, Interventional, and Health services research
Cameroon exhibits a high and non-decreasing level of maternal mortality (roughly 600 per 100,000 live births), partially related to its relatively high total fertility rate (roughly 4.6). Survey evidence furthermore suggests that a significant fraction of these pregnancies is unwanted or considered mistimed by the mother, especially among females aged 15-19. Despite this, the rate of utilization of family planning (FP) is low: e.g. only 48% of sexually active unmarried women use any form of (modern) contraception, or MC, and even then, it is primarily condoms. The use of LARCs (long-acting reversible contraceptives, i.e. the IUD and implant) is less than 1% according to the most recent Demographic Health Survey.
The study investigators propose to use an integrated behavioral science approach to increase the take-up of both SARCs (short-acting reversible contraceptives, i.e. the pill and injectable) and especially LARCs among reproductive-age females in Cameroon, including adolescents who may be unmarried and/or nulliparous. In addition to decreasing maternal mortality and undesired pregnancies, indirect effects for the community will include: increased welfare from reduced side effects that arise due to current one-size-fits-all FP counseling; healthier children due to improved birth spacing; and increased human capital formation both for children and for young (often school-aged) potential mothers.
The study investigators propose to conduct the study at HGOPY for a duration of 12 months. The study investigators will provide tablets to each of five nurses that conduct FP counseling to participants at the hospital. The tablets contain a counseling "app" (or decision-support tool or a job-aid) that was jointly developed by professionals from HGOPY, the World Bank, and the Ministry of Health. The study investigators propose an individually-randomized experiment, where the participants will be offered randomly varying discounts for the modern contraceptive methods they wish to adopt. The study investigators also propose to experiment with certain aspects of the "app" to improve its effectiveness - both for the participant and for the nurse. More details on the experimental design are provided below.
132 studies on the registry are indexed under Contraception Behavior; 20 are open to participants now.
This study's enrollment of 2,500 is above the median of 382 across 106 interventional studies indexed under Contraception Behavior.
Browse Contraception Behavior studies →World Bank is the lead sponsor of 11 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
* No exclusion criteria
Free SARC, Free LARC, Sequential recommendation
Behavioral: Price discounts for SARCs · Behavioral: Price discounts for LARCs
Free SARC, LARC=500 CFA, Sequential recommendation
Behavioral: Price discounts for SARCs · Behavioral: Price discounts for LARCs
Free SARC, LARC=1000 CFA, Sequential recommendation
Behavioral: Price discounts for SARCs · Behavioral: Price discounts for LARCs
Free SARC, LARC=2140 CFA, Sequential recommendation
Behavioral: Price discounts for SARCs · Behavioral: Price discounts for LARCs
Free SARC, LARC=5000 CFA, Sequential recommendation
Behavioral: Price discounts for SARCs
Regular price SARC, Free LARC, Sequential recommendation
Behavioral: Price discounts for LARCs
Regular price SARC, LARC=500 CFA, Sequential recommendation
Behavioral: Price discounts for LARCs
Regular price SARC, LARC=1000 CFA, Sequential recommendation
Behavioral: Price discounts for LARCs
Regular price SARC, LARC=2140 CFA, Sequential recommendation
Behavioral: Price discounts for LARCs
Regular price SARC, LARC=5000 CFA, Sequential recommendation
Free SARC, Free LARC, Simultaneous recommendation
Behavioral: Price discounts for SARCs · Behavioral: Price discounts for LARCs · Behavioral: Sequential vs. simultaneous recommendations
Free SARC, LARC=500 CFA, Simultaneous recommendation
Behavioral: Price discounts for SARCs · Behavioral: Price discounts for LARCs · Behavioral: Sequential vs. simultaneous recommendations
Free SARC, LARC=1000 CFA, Simultaneous recommendation
Behavioral: Price discounts for SARCs · Behavioral: Price discounts for LARCs · Behavioral: Sequential vs. simultaneous recommendations
Free SARC, LARC=2140 CFA, Simultaneous recommendation
Behavioral: Price discounts for SARCs · Behavioral: Price discounts for LARCs · Behavioral: Sequential vs. simultaneous recommendations
Free SARC, LARC=5000 CFA, Simultaneous recommendation
Behavioral: Price discounts for SARCs · Behavioral: Sequential vs. simultaneous recommendations
Regular Price SARC, Free LARC, Simultaneous recommendation
Behavioral: Price discounts for LARCs · Behavioral: Sequential vs. simultaneous recommendations
Regular Price SARC, LARC=500 CFA, Simultaneous recommendation
Behavioral: Price discounts for LARCs · Behavioral: Sequential vs. simultaneous recommendations
Regular Price SARC, LARC=1000 CFA, Simultaneous recommendation
Behavioral: Price discounts for LARCs · Behavioral: Sequential vs. simultaneous recommendations
Regular Price SARC, LARC=2140 CFA, Simultaneous recommendation
Behavioral: Price discounts for LARCs · Behavioral: Sequential vs. simultaneous recommendations
Regular Price SARC, LARC=5000 CFA, Simultaneous recommendation
Behavioral: Sequential vs. simultaneous recommendations
SARCs are offered free to the client
LARCs are offered at lower prices to the client
Top ranked methods are presented to the client sequentially or simultaneously
The client adopted a LARC
using data from the counseling sessions
Time frame: 1-day
The client adopted a modern contraceptive method (LARC or SARC)
using data from the counseling sessions
Time frame: 1-day
Was the client treated with respect by the provider during the counseling session?
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Time frame: 2-weeks
Did the client trust the provider during the counseling session?
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Time frame: 2-weeks
Did the health provider give information about contraceptive methods that was easy to understand during the counseling session?
Self-reported indicator variable using follow-up surveys two weeks after counseling session
Time frame: 2-weeks
Client satisfaction with adopted contraceptive method
using 2-week and 16-week follow-up surveys
Time frame: 2-week and 16-week measurements
Discontinuation of adopted contraceptive method
using 2-week, 16-week, and 52-week follow-up surveys
Time frame: 2-week, 16-week, and 52-week measurements
Percentage of participants with unintended pregnancy within the time frame
using 16-week and 52-week follow-up surveys
Time frame: 16-week and 52-week measurements
Plan to share: Undecided — We will likely share de-identified anonymous participant data publicly after the trial ends and our analyses are completed.
No publications or documents are linked to this record.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
World Bank